Medicine and Dentistry
Post-Hoc Analysis
100%
Adjuvant Chemotherapy
100%
Cancer Surgery
100%
Randomized Clinical Trial
100%
Colorectal Cancer
100%
Pembrolizumab
100%
DNA Mismatch Repair
100%
Colon Carcinoma
100%
Clinical Trial
100%
Adverse Event
68%
Disease Free Survival
50%
Odds Ratio
20%
Postoperative Complication
14%
Stomach Perforation
14%
Arm
14%
Immunotherapy
14%
Hazard Ratio
10%
Cohort Analysis
10%
Logistic Regression Analysis
10%
Oxaliplatin
10%
Proportional Hazards Model
10%
Fluoropyrimidine
10%
Keyphrases
Timing of Adjuvant Chemotherapy
25%
High-risk Stage II
25%
Late Start
25%
Neoadjuvant Immunotherapy
14%
Ulcer Perforation
14%
Major Pathological Response
14%